Sharon Stoll, DO
Neurology · New Haven, CTNPI 1114211174
Payments from drug & device makers
Across 967 payments — averaging $850.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$290K
- Sanofi$128K
- AstraZeneca$99K
- EMD Serono, Inc.$83K
- Novartis$46K
- TG Therapeutics, Inc.$39K
- plus $138K from 18 others
Across 13 payments — averaging $2478.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$25K
- F. Hoffmann-la Roche AG$5K
- Genentech, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 259 | $290,257 |
| Sanofi | 109 | $127,803 |
| AstraZeneca | 98 | $99,097 |
| EMD Serono, Inc. | 92 | $83,173 |
| Novartis | 116 | $45,716 |
| TG Therapeutics, Inc. | 37 | $38,540 |
| Amgen(2 entities) | 40 | $38,107 |
| E.r. Squibb & Sons, L.L.C. | 23 | $25,593 |
| Genentech USA, Inc. | 41 | $18,236 |
| Sanofi US Services Inc. | 1 | $16,212 |
| Genentech, Inc. | 27 | $11,543 |
| Bristol Myers Squibb | 54 | $9,888 |
| Roche Products Limited | 9 | $9,077 |
| Novartis Pharma AG | 2 | $7,700 |
| AbbVie | 24 | $298 |
| Sanofi-aventis U.S. LLC | 5 | $285 |
| Eisai Inc. | 3 | $178 |
| Pfizer | 14 | $158 |
| Axsome Therapeutics, Inc. | 4 | $154 |
| Inspire Medical Systems, Inc. | 2 | $74 |
| Lilly USA, LLC | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $18 |
How this compares
$822,228 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in New Haven
- David RussellNew Haven$31.2M
- David HaflerNew Haven$3.5M
- Richard NowakNew Haven$1M
- Joachrim BaehringNew Haven$831K
- Kenneth MarekNew Haven$683K
- Mary BaileyNew Haven$630K
- Nils PetersenNew Haven$293K
- Guido FalconeNew Haven$292K
- Aline HerlopianNew Haven$272K
- Sylvia KurzNew Haven$253K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.